Dr. Agrawals Eye Hospital Fair Value
Dr. Agrawals Eye Hospital (DRAGARWQ) average fair value is ₹2873.14 across 6 valuation models — P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, Discounted Cash Flow (DCF), vs a current market price of ₹4857.75 (-40.85%), fair value range ₹420.0–₹8039.5. For live price and a broader fundamental view, visit DRAGARWQ stock price BSE.
Fair Value Analysis Export
DRAGARWQ Fair Value vs Current Price — Valuation Summary
DRAGARWQ average fair value, fair value range, price gap and valuation status across 6 models: P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, Discounted Cash Flow (DCF). Explore DRAGARWQ Benjamin Graham valuation to estimate fundamental worth using multiple valuation models.
P/E Based Valuation
P/B Based Valuation
Price-to-Sales Valuation
Asset-Based Valuation
Benjamin Graham Number
Discounted Cash Flow (DCF)
DRAGARWQ Fair Value Analysis — Data Sources & Coverage
Dr. Agrawals Eye Hospital financial data sources, valuation methods applied and sector benchmarks used. Analyse DRAGARWQ FII DII holdings to track promoter, FII and institutional holdings.
Available Data Sources: Financial statements, dividend history, balance sheet data , sector comparisons.
DRAGARWQ vs Healthcare Services Sector Peers — P/E, P/B & Market Cap
Dr. Agrawals Eye Hospital P/E ratio, P/B ratio and market capitalisation vs Healthcare Services sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Suraksha Diagnostic | SURAKSHA | 40.64 | 5.71 | ₹1,356 |
| Deccan Health Care | DECCAN | 12.18 | 0.25 | ₹27 |
| Jupiter Life Line Hospit… | JLHL | 44.49 | 5.79 | ₹8,320 |
| One Global Service Provi… | ONEGLOBAL | 17.94 | 11.02 | ₹1,165 |
| Fortis Healthcare | FORTIS | 65.48 | 6.81 | ₹64,009 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.